Literature DB >> 2066426

Screening for heparin binding variants of antithrombin.

P L Harper1, M Daly, J Price, P F Edgar, R W Carrell.   

Abstract

A chromogenic assay for use as a screening test for the identification of antithrombin deficiency is described. The heparin concentration and the incubation time in the assay were optimised specifically to permit the detection of heparin binding defects of antithrombin. The sensitivity of antithrombin assays for the detection of this type of variant was significantly impaired when an incubation time of more than 30 seconds was used. Several commercially available assays recommend a longer incubation time than 30 seconds and therefore some patients with heparin binding defects of antithrombin may not be identified. The assay described here allows heparin binding variants of antithrombin to be identified and distinguished from other types of antithrombin deficiency in a simple two stage procedure.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 2066426      PMCID: PMC496828          DOI: 10.1136/jcp.44.6.477

Source DB:  PubMed          Journal:  J Clin Pathol        ISSN: 0021-9746            Impact factor:   3.411


  5 in total

Review 1.  Actions and interactions of antithrombin and heparin.

Authors:  R D Rosenberg
Journal:  N Engl J Med       Date:  1975-01-16       Impact factor: 91.245

Review 2.  Molecular genetics of inherited antithrombin III deficiencies.

Authors:  E V Prochownik
Journal:  Am J Med       Date:  1989-09-11       Impact factor: 4.965

Review 3.  Antithrombin III deficiency and thromboembolism.

Authors:  E Thaler; K Lechner
Journal:  Clin Haematol       Date:  1981-06

4.  Antithrombin (heparin cofactor) assay with "new" chromogenic substrates (S-2238 and Chromozym TH).

Authors:  U Abildgaard; M Lie; O R Odegård
Journal:  Thromb Res       Date:  1977-10       Impact factor: 3.944

5.  Heparin binding defect in a new antithrombin III variant: Rouen, 47 Arg to His.

Authors:  M C Owen; J Y Borg; C Soria; J Soria; J Caen; R W Carrell
Journal:  Blood       Date:  1987-05       Impact factor: 22.113

  5 in total
  1 in total

1.  Sulodexide ameliorates early but not late kidney disease in models of radiation nephropathy and diabetic nephropathy.

Authors:  Michele Rossini; Takashi Naito; Haichun Yang; Michael Freeman; Ellen Donnert; Li-Jun Ma; Stephen R Dunn; Kumar Sharma; Agnes B Fogo
Journal:  Nephrol Dial Transplant       Date:  2010-01-07       Impact factor: 5.992

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.